Indonesia opens first-ever plasma fractionation plant

GC Biopharma, a South Korean biopharmaceutical company, has announced that it has participated in the groundbreaking ceremony of a plasma fractionation plant held at Jababeka Industrial Estate in Indonesia, one of the company's overseas plant construction projects.

Backed by the Indonesian government's proactive support, the groundbreaking for what will become the nation's first-ever plasma fractionation plant was held after only 6 months following the Indonesian government's decision to approve the construction by GC Biopharma in June.

Eun-chul Huh, CEO of GC Biopharma, and Chung-Gwon Park, Representative Director of GC EM, took part in the ceremony organised by the Ministry of Health of Indonesia.

The plant will be built on a 40-thousand-m² land within the Jababeka Industrial Estate located 35km east from the nation's capital city of Jakarta. With the maximum capacity of 400 thousand liters of plasma fractionation a year, the plant aims to commence operation by 2027.

Since Indonesia has been relying 100% on the imported plasma-derived products, the groundbreaking for the plant marks the onset of local production journey of the nation's critical medical products, to which many government officials showed strong support by participating in the ceremony.  

GC Biopharma has obtained approval for the construction and technology transfer of plasma fractionation plant from the Indonesian government in June this year and signed a Memorandum of Understanding (MoU) with the Indonesian Red Cross and a local pharmaceutical company for the project.